Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Return on invested capital
Bio-Techne Corp's return on invested capital over the twelve months to 30 June 2026 was 7.70%. Over the past ten years it has ranged from 3.04% (fiscal 2025) to 11.4% (fiscal 2015); the current reading is higher than 58% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 7.70% | 4.66 |
| FY2025 | 3.04% | (2.74) |
| FY2024 | 5.78% | (3.07) |
| FY2023 | 8.85% | (1.99) |
| FY2022 | 10.8% | 2.02 |
| FY2021 | 8.82% | 2.11 |
| FY2020 | 6.71% | 0.62 |
| FY2019 | 6.09% | (0.79) |
| FY2018 | 6.88% | 0.24 |
| FY2017 | 6.64% | (4.07) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 24.1% |
| TECH Bio-Techne Corp | 7.70% |
| CORT Corcept Therapeutics Incorporated compare | 1.01% |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.97% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| IBRX ImmunityBio, Inc. compare | 0.00% |
| PCVX Vaxcyte, Inc. compare | −57.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −787.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement